Methemoglobinemia

Methemoglobinemia is a dyshemoglobinemia in which hemoglobin iron is oxidized from the ferrous (Fe²⁺) to the ferric (Fe³⁺) state, rendering it unable to bind and deliver oxygen to tissues. [1-2] It may be acquired (most common — drug/toxin-induced) or congenital (cytochrome b5 reductase deficiency, hemoglobin M disease). [3-4] Severe cases can cause cardiovascular collapse and death. [2]

• Exposure history is paramount: Ask about recent medications (dapsone, benzocaine, phenazopyridine, prilocaine, nitrates/nitrites, primaquine), procedures involving topical anesthetics (EGD, TEE, bronchoscopy), recreational drugs (amyl/isobutyl nitrite "poppers," cocaine), and occupational/environmental exposures (aniline dyes, nitrate-contaminated well water, herbicides such as propanil) [3][5-6]
• Timing of symptom onset relative to exposure (typically minutes to hours for direct oxidizers; may be delayed for metabolically activated agents like dapsone) [5]
• Symptom characterization: dyspnea, fatigue, headache, lightheadedness, nausea, anxiety [3][7]
• Severity and progression: worsening cyanosis, confusion, syncope, chest tightness [8-9]
• In neonates/infants: ask about contaminated well water, vegetable broth, diarrheal illness (increases susceptibility) [10-11]
• Intentional ingestion or suicidal intent should be assessed [8]

• Cyanosis unresponsive to supplemental oxygen — the hallmark red flag [5][12]
• Altered mental status: lethargy, stupor, seizures (MetHb >50%) [3][5]
• Cardiovascular collapse: hypotension, shock, cardiac arrhythmias (MetHb >55–70%) [2][5]
• Shock at presentation — the sole independent prognostic factor for mortality in a 10-year retrospective study [13]
• "Chocolate brown" blood that does not turn red on exposure to oxygen [8][14]
• Saturation gap: discordance between SpO₂ on pulse oximetry and SaO₂ on ABG [2][8]
• MetHb levels ≥70% are usually fatal [5]

Common causative agents (over two-thirds of clinically significant cases): [6]

• Benzocaine (topical anesthetic — highest risk among local anesthetics)
• Phenazopyridine (Pyridium)
• Dapsone (may cause rebound/chronic methemoglobinemia; cimetidine can reduce dapsone-mediated MetHb formation) [5][15]
• Nitrates/nitrites (nitroglycerin, sodium nitrite, amyl nitrite, dietary nitrates)
• Other: prilocaine, lidocaine (less common), primaquine, sulfonamides, nitric oxide (inhaled), metoclopramide, chloroquine [5][16]

Antidote — Methylene blue (methylthioninium chloride)

• Dose: 1 mg/kg IV over 5–30 minutes; may repeat once at 1 mg/kg after 1 hour if MetHb remains >30% or symptoms persist [15][17]
• Maximum 2 doses; if no response, consider alternative interventions [17]
• In moderate/severe renal impairment (eGFR 15–59): limit to a single dose of 1 mg/kg [17]

⚠️ Boxed Warning — Serotonin Syndrome: Methylene blue is a potent reversible MAO inhibitor. Avoid concomitant use with SSRIs, SNRIs, MAOIs, opioids, dextromethorphan, bupropion, buspirone, clomipramine, mirtazapine, and linezolid. [15] If methylene blue cannot be avoided, use the lowest possible dose and monitor for CNS toxicity for ≥4 hours. [15] Serotonergic drugs should not be taken within 72 hours after the last dose of methylene blue. [15]

Contraindications/cautions for methylene blue

• G6PD deficiency: methylene blue may be ineffective and can cause hemolysis (affects ~2% of the US population; real-time G6PD testing is rarely available) [1-2]
• Higher doses of methylene blue can paradoxically worsen methemoglobinemia via oxidizing effects [3]
• Prior anaphylaxis to methylene blue class products [15]

• Nitrate-contaminated well water is a recognized cause, particularly in infants ("blue baby syndrome")
• Contaminated or improperly stored vegetable broth (spinach, beets, carrots) has caused methemoglobinemia in infants [10]
• Dietary nitrites (cured meats, preserved foods) are generally low-risk in adults but may contribute in susceptible individuals
• No specific long-term dietary restrictions for acquired cases once the offending agent is removed

• Respiratory: dyspnea, shortness of breath (often out of proportion to exam findings)
• Neurological: headache, dizziness, confusion, syncope, seizures, lethargy
• Cardiovascular: chest pain, palpitations, tachycardia
• GI: nausea, vomiting (may also indicate co-ingestion)
• Psychiatric: anxiety, agitation (MetHb 20–50%) [3]
• Skin: cyanosis, gray/dusky discoloration — ask about onset and distribution

• Collateral: Witnesses to exposure, medication access, empty pill bottles, occupational chemical exposure, recreational drug use (poppers), suicidal ideation
• Family history: Lifelong cyanosis in family members suggests congenital methemoglobinemia — autosomal recessive cytochrome b5 reductase deficiency (CYB5R3 mutations) or autosomal dominant hemoglobin M disease [4][18]
  • Type I RCM: cyanosis only, benign course
  • Type II RCM: cyanosis + severe encephalopathy, microcephaly, dystonia, movement disorders, poor neurological prognosis [19]
• Consanguinity increases risk for recessive forms [20]

• Recent use of known oxidizing medications or topical anesthetics [3][6]
• Hospitalized patients have increased risk of topical anesthetic-induced methemoglobinemia [3]
• Comorbidities that impair oxygen transport: anemia, asthma, COPD, heart disease — lower MetHb levels may become symptomatic [3][14]
• Smoking increases baseline MetHb and susceptibility [3]
• Infants <6 months (lower cytochrome b5 reductase activity, higher fetal hemoglobin susceptibility) [21]
• G6PD deficiency (impaired reduction pathway, poor response to methylene blue) [2]
• Occupational exposure to aniline dyes, industrial chemicals, herbicides (propanil) [13]

• Cyanotic congenital heart disease (especially in neonates) — echocardiogram differentiates [22]
• Carbon monoxide poisoning — co-oximetry distinguishes; COHb elevated, MetHb normal [23]
• Cyanide poisoning — lactic acidosis, almond odor; may co-occur with smoke inhalation
• Sulfhemoglobinemia — irreversible; does not respond to methylene blue; co-oximeters may misidentify as MetHb [23]
• Severe pneumonia / ARDS / PE — hypoxemia responsive to supplemental O₂ (unlike methemoglobinemia)
• Sepsis/shock — peripheral cyanosis from poor perfusion
• Congenital methemoglobinemia — lifelong cyanosis, positive family history [4]

Key distinguishing feature: Cyanosis + failure to improve with supplemental O₂ + saturation gap (SpO₂ on pulse ox trends toward ~85% regardless of true oxygenation) [5][23]

• Prior episodes of methemoglobinemia (recurrence common with dapsone use) [15]
• G6PD deficiency (critical for treatment planning)
• Anemia, cardiopulmonary disease (lower threshold for symptoms)
• Congenital hemoglobinopathies
• Psychiatric history (intentional ingestion)
• Current serotonergic medications (impacts methylene blue safety) [15]
• Renal impairment (dose adjustment for methylene blue) [17]

• Vital signs: Tachycardia, tachypnea; hypotension in severe cases; SpO₂ characteristically plateaus around ~85% on pulse oximetry and does not improve with O₂ [5][23]
• Skin: Generalized cyanosis, gray/dusky/slate-blue discoloration disproportionate to respiratory effort [2-3]
• Blood appearance: Chocolate brown color that does not turn red when exposed to air or oxygen — a bedside diagnostic clue [8][14]
• Neurological: Altered mental status ranging from anxiety to obtundation, seizures at high levels [5]
• Cardiovascular: Tachycardia; arrhythmias and circulatory failure in severe cases [5]
• Respiratory: May have minimal auscultatory findings despite significant hypoxia

• Co-oximetry (ABG with co-oximetry) — the gold standard for diagnosis; directly measures MetHb fraction (normal <3%) [16][23]
• ABG: PaO₂ is typically normal (oxygen dissolved in plasma is unaffected); calculated SaO₂ will be falsely normal [23]
• CBC: Evaluate for concurrent hemolytic anemia (especially post-methylene blue in G6PD deficiency)
• Reticulocyte count, haptoglobin, LDH, bilirubin: If hemolysis suspected
• G6PD level: Important but rarely available in real time; consider sending for future reference [1]
• Lactate: Elevated in severe tissue hypoxia
• BMP/CMP: Renal function (methylene blue dose adjustment), electrolytes
• Toxicology screen: If co-ingestion suspected
• Methemoglobin reductase activity: For suspected congenital cases (send to reference lab) [18]

• No specific imaging is diagnostic for methemoglobinemia
• Chest X-ray: Typically normal; useful to exclude pulmonary causes of cyanosis (pneumonia, pneumothorax, PE)
• Echocardiogram: In neonates to exclude cyanotic congenital heart disease [22]
• CT angiography: Only if PE is in the differential
• Imaging is generally unnecessary once the diagnosis is confirmed by co-oximetry

• Bedside "brown blood" test: Place a drop of patient blood on white filter paper next to a normal control — methemoglobinemic blood remains chocolate brown while normal blood turns bright red on exposure to oxygen [14]
• Co-oximetry (point-of-care or lab-based): Measures oxyhemoglobin, deoxyhemoglobin, carboxyhemoglobin, and methemoglobin fractions [23]
• Pulse oximetry limitations: Standard pulse oximeters measure only two wavelengths and are unreliable in methemoglobinemia — SpO₂ trends toward ~85% regardless of actual MetHb level [5][23]
• Hemoglobin electrophoresis: For suspected hemoglobin M disease [11]
• CYB5R3 gene sequencing: For suspected congenital cytochrome b5 reductase deficiency [20]

• ECG should be obtained in all symptomatic patients to evaluate for ischemia and arrhythmias
• Reported ECG changes include ST-segment changes and T-wave abnormalities consistent with myocardial ischemia from impaired oxygen delivery [24]
• Severe methemoglobinemia (>55%) can cause cardiac arrhythmias and circulatory failure [5]
• Sinus tachycardia is common
• ECG is also important to evaluate for co-ingestant effects (e.g., QTc prolongation)

Severity stratification by MetHb level: [3][5]

Patients with underlying cardiopulmonary disease, anemia, or smoking may become symptomatic at lower MetHb levels. [3][14] Dapsone and aryl amine exposures may cause rebound methemoglobinemia after initial treatment due to prolonged half-life of the parent compound. [15]

Initial stabilization

• ABCs, high-flow supplemental oxygen (does not treat MetHb directly but maximizes dissolved O₂) [13]
• Identify and remove the offending agent immediately
• Continuous cardiac monitoring

Methylene blue (first-line antidote): [2][17]

• Indication: MetHb ≥30%, or symptomatic at any level
• Dose: 1 mg/kg IV over 5–30 minutes
• May repeat 1 mg/kg after 1 hour if MetHb remains >30% or symptoms persist
• Dilute in 50 mL D5W (avoid normal saline — chloride reduces solubility) [17]
• Do not exceed 2 doses; if no response, pursue alternatives [17]
• Expect response within minutes; 95.5% of patients achieved ≥50% MetHb reduction in a prospective registry [15]

If methylene blue fails or is contraindicated (G6PD deficiency, serotonergic drug use): [1-2]

• Exchange transfusion — most established alternative
• Ascorbic acid (vitamin C) — slow onset, requires multiple doses over hours; useful as adjunct or when methylene blue unavailable [2][25]
• Hyperbaric oxygen — limited availability; delayed effect (hours); impractical in hemodynamic instability [2]
• N-acetylcysteine — not effective (failed in a controlled volunteer study) [2]

For dapsone-induced chronic methemoglobinemia: Cimetidine co-administration can reduce MetHb formation [5]

• Admit to ICU: MetHb >30%, hemodynamic instability, shock, altered mental status, need for methylene blue with rebound risk (dapsone), or failure to respond to treatment [13]
• Admit to monitored bed: MetHb 20–30% with symptoms, significant comorbidities, or need for observation after methylene blue
• Observation/discharge considerations: MetHb <20% with mild or no symptoms, rapid response to methylene blue, short-acting causative agent (e.g., benzocaine), no comorbidities — may be observed 4–6 hours and discharged if MetHb normalizes and symptoms resolve
• Dapsone exposures require prolonged monitoring (≥24–72 hours) due to rebound risk from long half-life [15]
• Poison control consultation recommended for all significant cases [6]
• Hematology consultation for suspected congenital methemoglobinemia or G6PD-related hemolysis
• Psychiatry consultation if intentional ingestion

• Follow-up timing: Within 24–48 hours for discharged patients; sooner if dapsone or long-acting agent involved
• Return immediately for: Recurrence of cyanosis, worsening dyspnea, chest pain, confusion, syncope, dark urine (hemolysis)
• Patient counseling:
  • Avoid the offending agent in the future; document allergy/adverse reaction
  • Patients on serotonergic drugs should avoid serotonergic medications for 72 hours after methylene blue [15]
  • Advise against driving or operating machinery until neurologic and visual symptoms resolve [15]
• Expected recovery: Most patients with acquired methemoglobinemia recover rapidly after methylene blue administration (median time to ≥50% MetHb reduction ~2.9 hours) [15]
• Congenital cases: Lifelong management with daily oral methylene blue and/or ascorbic acid; genetic counseling for families [4][11]

1. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Lavonas EJ, Akpunonu PD, Arens AM, et al. Circulation. 2023.

2. Part 10: Adult and Pediatric Special Circumstances of Resuscitation: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Cao D, Arens AM, Chow SL, et al. Circulation. 2025.

3. Risk of Topical Anesthetic–Induced Methemoglobinemia: A 10-Year Retrospective Case-Control Study. — Chowdhary S, Bukoye B, Bhansali AM, et al. JAMA Internal Medicine. 2013.

4. Autosomal recessive congenital methemoglobinemia. — National Library of Medicine (MedlinePlus) 2015.

5. Drug-Induced Methaemoglobinaemia. Treatment Issues. — Coleman MD, Coleman NA. Drug Safety. 1996.

6. Causative Agents in Clinically Significant Methemoglobinemia: A National Poison Data System Study. — Wills BK, Cumpston KL, Downs JW, Rose SR. American Journal of Therapeutics. 2020.

7. A Case of Dapsone-Induced Methaemoglobinaemia. — Tan YA, Ng KC, Cheo SW, Khoo TT, Low QJ. Clinical Medicine. 2020.

8. Methemoglobinemia Secondary to Inhalation of Automobile Emissions With Suicide Motivations. — Tazón-Varela MA, Padilla-Mielgo Á, Villaverde-Plazas R, et al. Journal of Clinical Medicine. 2023.

9. Case Report of Methemoglobinemia: An Illustration That It Is Time to Report All Results With Arterial and Venous Blood Gas Result Reporting. — Shelton D, Dashi G, Cheung M, Sindall T. The Journal of Emergency Medicine. 2020.

10. Acquired Methemoglobinemia in Children Presenting to Italian Pediatric Emergency Departments: A Multicenter Report. — Raucci U, Stanco M, Roversi M, et al. Clinical Toxicology. 2022.

11. Congenital Methemoglobinemia: A Rare Cause of Cyanosis in the Newborn--a Case Report. — Da-Silva SS, Sajan IS, Underwood JP. Pediatrics. 2003.

12. Acquired Methemoglobinemia in the Surgical Intensive Care Unit. — Tackett N, Mathews T, Mentzer C, et al. The American Surgeon. 2023.

13. A 10-Year Retrospective Study of Patients With Acquired Methemoglobinemia: Causative Agents, Clinical Characteristics, and Outcomes. — Tansuwannarat P, Bualerd P, Rittilert P, Tongpoo A, Trakulsrichai S. Clinical Toxicology. 2026.

14. Methemoglobinemia: Pathogenesis, Diagnosis, and Management. — Skold A, Cosco DL, Klein R. Southern Medical Journal. 2011.

15. FDA Drug Label. — Updated date: 2026-04-02. Food and Drug Administration.

16. Methemoglobinemia in the Operating Room and Intensive Care Unit: Early Recognition, Pathophysiology, and Management. — Cefalu JN, Joshi TV, Spalitta MJ, et al. Advances in Therapy. 2020.

17. FDA Drug Label. — Updated date: 2025-11-19. Food and Drug Administration.

18. Recessive Congenital Methaemoglobinaemia: Cytochrome B(5) Reductase Deficiency. — Percy MJ, Lappin TR. British Journal of Haematology. 2008.

19. Recessive Hereditary Methaemoglobinaemia, Type II: Delineation of the Clinical Spectrum. — Ewenczyk C, Leroux A, Roubergue A, et al. Brain : A Journal of Neurology. 2008.

20. Mutation Update: Variants of the CYB5R3 Gene in Recessive Congenital Methemoglobinemia. — Gupta V, Kulkarni A, Warang P, et al. Human Mutation. 2020.

21. FDA Drug Label. — Updated date: 2023-05-30. Food and Drug Administration.

22. Congenital Methemoglobinemia Identified by Pulse Oximetry Screening. — Ward J, Motwani J, Baker N, et al. Pediatrics. 2019.

23. Laboratory Assessment of Oxygenation in Methemoglobinemia. — Haymond S, Cariappa R, Eby CS, Scott MG. Clinical Chemistry. 2005.

24. Understanding the EKG Changes in Methemoglobinemia. — Arun Kumar P, Dasari M, Sahu KK, Al-Seykal I, Mishra AK. Annals of Hematology. 2022.

25. Methemoglobinemia in a Case of Paint Thinner Intoxication, Treated Successfully With Vitamin C. — Dhibar DP, Sahu KK, Jain S, Kumari S, Varma SC. The Journal of Emergency Medicine. 2018.